|
11.7.2016 |
EN |
Official Journal of the European Union |
C 251/46 |
Action brought on 30 May 2016 — Viridis Pharmaceutical v EUIPO — Hecht-Pharma (Boswelan)
(Case T-276/16)
(2016/C 251/53)
Language in which the application was lodged: German
Parties
Applicant: Viridis Pharmaceutical (Tortola, British Virgin Islands) (represented by: C. Spintig, S. Pietzcker and M. Prasse, lawyers)
Defendant: European Union Intellectual Property Office (EUIPO)
Other party to the proceedings before the Board of Appeal: Hecht-Pharma GmbH (Hollnseth, Germany)
Details of the proceedings before EUIPO
Proprietor of the trade mark at issue: Applicant
Trade mark at issue: European Union word mark ‘Boswelan’ — European Union trade mark No 3 381 563
Procedure before EUIPO: Revocation proceedings
Contested decision: Decision of the Fifth Board of Appeal of EUIPO of 29 February 2016 in Case R 2837/2014-5
Form of order sought
The applicant claims that the Court should:
|
— |
annul the contested decision in so far as it rejects the applicant’s appeal against the declaration of the revocation of European Union trade mark No 003381563 in relation to ‘medicinal products for the treatment of multiple sclerosis’; |
|
— |
order EUIPO to pay the applicant’s costs. |
Pleas in law
|
— |
Infringement of Article 51(1)(a) of Regulation No 207/2009 — Genuine use of the mark; |
|
— |
Infringement of Article 51(1)(a) of Regulation No 207/2009 — Proper reasons for non-use of the mark; |
|
— |
Infringement of Article 83 of Regulation No 207/2009, in particular infringement of the principle of the protection of legitimate expectations. |